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Institute of Cellular Medicine, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UKSummary to epigenetic regulation; DNA by attachment of methyl group toAn important discovery from the human genomemapping project
was that it is comprised of a surprisingly low number of genes,
with recent estimates suggesting they are as few as 25,000 [1].
This supported an alternative hypothesis that our complexity in
comparison with lower order species is likely to be determined
by regulatory mechanisms operating at levels above the funda-
mental DNA sequences of the genome [2]. One set of mechanisms
that dictate tissue and cellular complexity can be described by the
overarching term ‘‘epigenetics’’. In the 1940s, ConradWaddington
described epigenetics as ‘‘the branch of biology which studies the
causal interactions between genes and their products which bring
the phenotype into being’’. Today we understand epigenetics as a
gene regulatory system comprised of 3majormechanisms includ-
ing DNA modiﬁcations (e.g., methylation), use of histone variants
and post-translational modiﬁcations of the amino acid tails of
histones and non-coding RNAs of which microRNAs are the best
characterized [3,4]. Together, these mechanisms orchestrate
numerous sets of chemical reactions that switch parts of the
genome on and off at speciﬁc times and locations.
Epigenetic marks, or the epigenome, exhibit a high degree of
cellular-speciﬁcity and developmental or environmentally driven
dynamic plasticity. Due to being at the interface between genome
and the environment, the epigenome evolves at a very high rate
compared to genetic mutations. Indeed, the differences in the epi-
genome account for most of the phenotypic uniqueness between
closely related species, especially primates. More interestingly,
the epigenetic changes, or epimutations, within an individual are
not only maintained over cellular generations, but may also be
transmitted between generations, such that adaptive epimutations
generated in response to a particular environmental cue can inﬂu-
ence phenotypes in our children and grandchildren [5].
Chromatin structure and non-coding RNAs
Genomic DNA in the nucleus is not present in a naked form, but
rather it is associated with small proteins called histones to make
a structure termed chromatin. Both DNA and histones are subjectJournal of Hepatology 20
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dinucleotide (CpG) and histones by attachment of a number of
chemical groups to speciﬁc amino acid residues (histone modiﬁ-
cations) [4,6]. These two major epigenetic mechanisms will be
considered in further detail in the latter sections.
Non-coding RNAs play an increasingly appreciated and crucial
role in epigenetic regulation. Broadly, non-coding RNAs can be
divided into long and short species, both of which play prominent
but very separate roles in gene regulation. It is now known that
only 1% of the mammalian genome codes for proteins, however
70–90% of the entire genome is transcribed at some point during
the lifetime to produce a large transcriptome of long non-coding
RNAs (lncRNAs) [7,8]. They are a class of messenger RNA-like
transcripts that lack any discernible open reading frame [7]. Long
ncRNAs are often poorly conserved, characterized by low copy
number, fast turnover rates as well as very long length, ranging
from 200 nucleotides up to 100 kilobases, sometimes encompass-
ing a whole chromosome [9]. Due to their length, these RNA spe-
cies offer the possibility of allele-speciﬁc action and targeting of a
single location within the genome. This is in contrast to transcrip-
tion factors or small non-coding RNAs that bind a short DNA
sequence which may be repeated numerous times throughout
the genome [7]. Although function of many lncRNAs is yet to
be illuminated, it is now clear that at least some lncRNAs play
a role in processes that lead both to gene activation and repres-
sion. This is at least in part achieved by the ability of lncRNAs
to guide the catalytic function of chromatin-modifying enzymes
to speciﬁc sites in the genome, and these complexes then act
on chromatin modiﬁcations and structure [7,10]. Currently, there
are no lncRNAs with assigned role in liver disease; however, there
have been excellent examples within other disease contexts, such
as MALAT1 (metastasis-associated lung adenocarcinoma tran-
script 1), which is a highly conserved lncRNA that regulates
metastasis development in lung cancer by activating expression
of metastasis-associated genes [11]. Latest studies have shown
that antisense oligonucleotides can be used to silence MALAT1
and thus prevent metastatic disease [11,12]. It will be exciting
to learn the potential roles of lncRNAs in liver disease and to ﬁnd
out whether similar antisense silencing regimes may have a ther-
apeutic impact.
MicroRNAs (miR) are a class of short (20–24 nucleotide) non-
coding RNAs that regulate gene expression at a post-transcrip-
tional level, through binding to the 30-untranslated region of tar-
geted messenger RNA and causing its degradation or
destabilization; alternatively miRs can also effect translational13 vol. 59 j 1349–1353
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repression [13]. The observed outcome is a modest change in
gene expression, widely deﬁned as a ‘‘ﬁne-tuning effect’’ [14].Histone modifications
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Fig. 1. Epigenetic mechanisms that regulate gene expression. The mammalian
genome is packaged in the nucleus via wrapping of DNA around histones, forming
a structure known as chromatin. The on and off state of gene expression is
regulated by DNA methylation, post-translational modiﬁcations of various
residues within histone tails, and non-coding RNAs.microRNAs and liver disease: intriguing transformation from
basic science into clinics
In humans, over 1500miRs have been identiﬁedwhich in turn tar-
get hundreds of genes within numerous biological pathways
including liver development, regeneration, and ﬁbrosis. miRNA
proﬁling of distinctive liver diseases including chronic hepatitis
C and B, NAFLD (nonalcoholic fatty liver disease), ALD (alcoholic
liver disease), and drug-induced liver injury have revealed miRs
that are now becoming novel therapeutic targets in various clini-
cal conditions [15,16]. One of the best examples of such new
developments is the discovery of miR-122 role in hepatitis C
[17]. miR-122 was shown to facilitate HCV replication by binding
to multiple sites in the 50 untranslated region of HCV RNA genome
and enhances translation of the viral proteins and protect HCV
RNA against nucleolytic degradation. In vivo targeting of miR-
122 was initially tested in chimpanzees where 12-week intrave-
nous delivery of locked-nucleic-acid-[LNA]-modiﬁed complemen-
tary oligonucleotide led to depletion of miR-122 and durable
reduction in HCV RNA levels as well as lower serum cholesterol
levels [19]. Phase I and IIa human trials with Miravirsen (LNA-
modiﬁed-antimiR-122) have also revealed good safety proﬁles
and tolerability with prolonged reduction in HCV RNA following
18 weeks of treatment [20]. In addition, miR-122 is a mediator
of insulin, lipid metabolism, and iron homeostasis. Antagonism
of miR-122 reduces cholesterol and LDL levels through affecting
hepatic cholesterol and fatty acid biosynthesis genes while induc-
ing b oxidation of fatty acids as well as causing iron deﬁciency
with lower levels of plasma and liver iron [18]. As such, antagon-
ising miR-122 may have multiple beneﬁcial outcomes.
While antagonism of miR-122 shows very encouraging
results, two remarkable papers, using germline and liver-speciﬁc
knockout mice, highlighted some unexpected roles of miR-122 in
the liver. Mice with miR-122 deletions had reduced serum cho-
lesterol levels similar to the pharmacological inhibition of miR-
122, however, they developed microsteatosis with triglyceride
accumulation, steatohepatitis with inﬂammatory cell recruit-
ment, and elevated pro-inﬂammatory mediators (IL-6, TNF-a)
[21]. Liver ﬁbrosis, via the activation of KLF6 axis, and hepatocel-
lular carcinoma-like tumours were also evident in this pheno-
type, indicating tumour suppressor properties of miR-122 [22].
With our current knowledge, the reason for the biological distinc-
tion between the temporary pharmacological inhibition and the
global deletion of miR-122 is not yet known. However, it is likely
that our current understanding of the mechanisms by which
microRNAs operate in these systems is rather one-dimensional.
With further research and improved insight into the ways in
which various epigenetic regulatory aspects integrate with one
another, we might discover means of manipulating homeostasis
as well as disease states.Histone modiﬁcations and liver disease: still on the bench
As already stated, DNA inside the nuclei is complexed with his-
tones, forming a structure termed chromatin. The main histone
proteins are called histone H2A, histone H2B, histone H3, and his-
tone H4 [4,6]. The smallest unit of chromatin is a mononucleo-
some, which consists of 146 base pairs of genomic DNA1350 Journal of Hepatology 2013sequence which is wrapped around an octamer of histones- two
copies of each of the histones H2A, H2B, H3, and H4 (Fig. 1).
Histones are small, globular proteins with long ’tails’ on one end
of the amino acid structure, this being the location of post-trans-
lational modiﬁcations carried out by numerous enzymes. There
are in excess of 60 sites within each octamer of histones that are
subject to chemical modiﬁcation. Modiﬁcations include methyla-
tion, citrullination, acetylation, phosphorylation, SUMOylation,
ubiquitination, and ADP-ribosylation. Combinations of various
chemical groups are attached to the histone tails which then form
binding sites for protein complexes that are able to affect tran-
scriptional activity of a particular gene. Histone modiﬁcations
are also able to induce conformational changes in chromatin such
to promote transcription or silencing of gene expression in varying
degrees. Both of these processes depend on the site, type, and
number of chemical groups attached to the histone tails [4,6,23].
As there are strings of histone octamers at every 146 base pairs
of DNA sequence along the gene, and each one can have a partic-
ular set of modiﬁcations at one of over 60 sites, the possible com-
binations that can be achieved are huge [4]. Each combination of
histone marks potentially provides a speciﬁc recognition site for
a protein complex that can alter chromatin structure. In that
sense, the histone modiﬁcations provide a complex blueprint that
regulates transcriptional activity, which is also referred to as the
histone code [4].
In terms of a functional outcome, histone acetylation almost
invariably underpins induction of gene transcription; however,
methylation of lysine residues within the histone tail can either
stimulate (histone 3 lysine 4) or inhibit gene expression (histonevol. 59 j 1349–1353
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Fig. 2. Enzymes that control histone lysine methylation and acetylation are
targets for numerous drugs that are being developed or already used
clinically. HDAC, histone deacetylase; HAT, histone acetyltransferase; KMT,
histone lysine methyltransferas; KDM, histone lysine demethylase.
JOURNAL OF HEPATOLOGY3 lysine 9 or 27 methylation) (please see Fig. 2 for a list of com-
pounds that target histone methylation and acetylation). The
acetylation of histones is carried out by two groups of enzymes,
histone acetyl transferases (HAT) and histone deacetylases
(HDAC) (Fig. 2). Among histone modifying enzymes, HDACs have
received most attention. The role of HDAC3 in circadian regula-
tion, hepatic energy metabolism, and hepatosteatosis has now
been clearly demonstrated [24]. HDAC3 negatively regulates lip-
ogenic genes and directs metabolic sources towards gluconeo-
genesis to maintain normal blood glucose during daytime. In
contrast, HDAC3 is signiﬁcantly downregulated at night, which
stimulates lipid synthesis. Interestingly, liver-speciﬁc knockdown
of HDAC3 leads to the development of marked steatosis, with tri-
glyceride accumulation and ‘‘insulin hypersensitivity’’. Similarly,
alcohol-induced microsteatosis is associated with reduced
HDAC3 expression. Furthermore, alcohol and its metabolite ace-
tate induce acetylation of histones globally in macrophages and
hepatocytes, particularly in promoters of pro-inﬂammatory cyto-
kines [25].
Pharmacological targeting of histone modifying enzymes, par-
ticularly inhibitors of HDACs, constitutes a rapidly growing com-
ponent of the epigenetic drug market. Two HDAC inhibitors are
currently licensed for use in haematological malignancies and
similar drugs are in clinical trials for various hematogenous
malignancies and solid organ tumors (Fig. 2) [please refer to clin-Journal of Hepatology 2013ical trials links under Refs. 26,27]. In vitro and in vivo studies sug-
gest that HDACs are considerably upregulated in chronic liver
disease; this led to research using HDAC inhibitors (HDACi) to
block myoﬁbroblast generation and ﬁbrogenesis. Laboratory evi-
dence suggests that various HDACi attenuate the activation of
hepatic stellate cells and ﬁbrosis in animal models. However,
the mechanism of action of the HDACi was not clearly understood
and, of note, it is now known that HDACs and their inhibitors
have effects on non-histone proteins such as cytoskeleton pro-
teins. For HDACs to be fully exploited for therapeutic purposes,
it will be necessary to have a much deeper understanding of their
activities and substrates. In addition, we will need histone mod-
iﬁers with greater speciﬁcity; two examples of this approach
were recently reported using highly selective inhibitors of EZH2
histone methyltransferase and jumonji H3K27 histone demethyl-
ase, which demonstrated antitumorigenic activity in lymphoma
cells and modulated macrophage response, respectively [28,29].DNA methylation, methyl-binding proteins and liver disease:
astonishing roles – prepare for lift off
Methylation of DNA occurs at the 5th carbon in the pyrimidine
ring of cytosine nucleotides and most commonly in cytosine
phosphoguanine dinucleotides, often referred to as CpGs. Large
(longer than 200 bp) and dense (>55%) clusters of CpG sequences
are termed CpG islands. Many human gene promoters contain
clusters of CpG islands in the unmethylated state; in contrast,
most non-promoter CpGs are methylated [30]. The functional
role of DNA methylation is relatively complicated, but generally
speaking, methylation within the promoter regions ordinarily
leads to transcriptional repression, whereas methylation within
gene body can exert transcriptional activation. Two main mecha-
nisms have been described for DNA methylation-mediated long-
term gene silencing. Methylated DNA can either repress gene
expression by recruiting methyl-binding proteins (MeCP2,
MBD1–4) that in turn interact with chromatin silencing protein
complexes, or it may directly interfere with the binding of tran-
scription factors to their DNA sequence recognition motifs [30].
Methylation of DNA is executed by enzymes known as DNA
methyltransferases (Dnmt) using S-adenosyl methionine as the
methyl donor [30]. It is not clear how DNA methylation is tar-
geted to a particular region, but it is likely to involve interaction
of DNMTs with other chromatin associated factors [30].
The transdifferentiation of hepatic stellate cells (HSC) into a
myoﬁbroblast-like phenotype is a pivotal event in hepatic
wound-healing and ﬁbrosis. The dramatic change in phenotype
associated with HSC transdifferentiation is underpinned by a glo-
bal change in gene expression. DNA methylation exists in a num-
ber of genes that are expressed at a high level in quiescent HSCs,
which are then silenced as the cells activate. At present it is
unclear as to whether the DNA methylation pattern of the HSC
genome alters with transactivation, however, there is evidence
that the way in which the cell ‘‘reads’’ the so-called epigenome
does change [31]. As HSCs transdifferentiate, they begin to
express MeCP2, a DNA methyl-binding protein that is recruited
to methyl-CpG marks present on the DNA and upon binding
can subsequently recruit chromatin remodeling complexes that
silence gene transcription. This type of gene silencing mechanism
occurs at the IjBa and PPAR-c genes in activated HSCs, which is
required for these cells to acquire their inﬂammatory andvol. 59 j 1349–1353 1351
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ﬁbrogenic phenotype [31,32]. In addition to its repressive action,
MeCP2 can also act as a transcriptional activator, although the
mechanisms by which it achieves this apparently paradoxical
effect are not yet clear. A recent report suggested that modiﬁca-
tion of methyl-CpG to hydroxymethyl-CpG enables MeCP2 to
function as a stimulator of transcription [33]. We have previously
reported that MeCP2 enhances the expression of other histone
modifying enzymes such as the histone methyltransferases
EZH2 and ASH1 [31,34]. These enzymes in turn regulate the
attachment of methyl groups to histone H3 lysine 27 (EZH2)
and histone H3 lysine 4 (ASH1). Because H3K27 methylation is
a transcriptionally repressive mark, EZH2 therefore regulates
silencing of target genes, such as PPAR-c [31]. In contrast,
methylation of lysine 4 of histone H3 is a signature of actively
transcribed genes [6]. During HSC transdifferentiation, ASH1 is
recruited to the regulatory regions of the collagen 1A1, TIMP1
and TGFb1 where it facilitates their transcription [34]. Taken
together, MeCP2 acts as a pivotal regulator of HSC activation,
and it is worth noting thatMeCP2 gene deletion or drug mediated
EZH2-inhibition attenuates hepatic ﬁbrosis. Rosemarinic acid
and baicalin (active ingredient of Yang-Gan-Wan, Chinese
herbal preparation) also repress MeCP2-EZH2 relay, thus
allowing re-expression of PPAR-c, which in turn prevents hepatic
ﬁbrosis [35].
DNA methylation, MeCP2, EZH2, and ASH1 may be bona ﬁde
therapeutic targets for prevention and/or treatment of liver ﬁbro-
sis. It is very well worth noting the manner in which DNA meth-
ylation, methyl binding proteins and enzymes that control
histone modiﬁcations are involved in crosstalk, and it will be cru-
cial to understand these interactions in order to develop drugs
that will target these pathways.Epigenetic marks are heritable by future generations
Genetic studies exploring the association of single nucleotide
polymorphisms and chronic liver diseases created fundamental
data regarding the variability of disease development (e.g.,
NAFLD and PNPLA3) and treatment responses (e.g., hepatitis C
and IL28B). However, there remains a signiﬁcant gap in our
understanding of liver patho-physiology. Liver ﬁbrosis is a ﬁnal
common pathway of liver injury irrespective of aetiology, how-
ever, it is currently not clear if predisposition to development
of ﬁbrosis exists or indeed if existence of disease in previous gen-
erations alters such predisposition. We recently described the
potential for transgenerational epigenetic transmission of sus-
ceptibility traits for liver ﬁbrosis in male rats [5]. Offspring from
a lineage of two consecutive generations of ancestors that suf-
fered liver ﬁbrosis, upon injury with the hepatotoxin carbon tet-
rachloride, developed less ﬁbrosis compared with rats that had
no ancestral history of liver disease. The adapted response was
characterized by reduced numbers of myoﬁbroblastic HSC,
reduced expression of proﬁbrogenic TGFb1, and elevated expres-
sion of antiﬁbrogenic PPAR-c and PPAR-a. Interrogation of DNA
methylation at the PPAR-c and PPAR-a promoters revealed that
ancestral liver disease leads to hypomethylation of these regula-
tory regions in the livers of offspring. Intriguingly, in a NAFLD
cohort, patients with severe ﬁbrosis or cirrhosis had higher levels
of PPAR-c promoter DNA methylation as compared to patients
with mild ﬁbrosis [5]. This study therefore provides evidence of
heritable epigenetic signatures that can be modiﬁed in response1352 Journal of Hepatology 2013to injurious stimuli to allow rapid adaptation to limit the ﬁbro-
genic response and preserve normal liver architecture. It also
raises the exciting possibility of epigenetic screening of liver
patients for prognosis of disease progression.Conclusions
Complex genetic and environmental interactions give rise to the
phenotype of an individual. This phenotype is then subject to life-
long change through remodeling of the individual’s epigenome.
The underlying epigenetic mechanisms can also impact on the
course of diseases or chronic conditions that the individual may
suffer, such that they can restrict or promote their progression.
The challenge now lies in fully understanding the epigenetic
mechanisms and their interaction, which is a tall order due to
the complexity of the system. With much improved knowledge,
we might be able to selectively modulate epigenome through
the use of drugs, alteration in diet, or applying other types of
interventions in order to alter the course of disease and ageing.
Key Points 
Clinical application of epigenetics in Hepatology
• May be used as biomarkers of liver injury or fibrosis 
from blood/plasma-based on necrotic or apoptotic cells 
released from injured liver, free microRNA released 
from cells or exosome associated microRNA
• May be used as prognostic indicators of disease 
activity from liver/blood - tight regulation compared to 
gene expression changes, which may solve sample 
variability
• May predict treatment response
• Can provide new avenues for therapeutic application- 
microRNA inhibition by oligonucleotide inhibitors or 
microRNA delivery/potentiating the effect by miRNA 
mimics, inhibitors of histone modifying enzymes, 
DNMT inhibitors
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